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Abstract A systematic exploration of the VH2/VU12^13 vari-
able domains of the anti-CD4 monoclonal antibody (mAb)
13B8.2 was performed by the Spot method to screen for
paratope-derived peptides (PDPs) demonstrating CD4 binding
ability. Nine peptides, named CB1 to CB9, were identified,
synthesized in a cyclic and soluble form and tested for binding to
recombinant soluble CD4. Among them, CB1, CB2 and CB8
showed high anti-CD4 activity. Competition studies for CD4
binding indicated that PDPs CB1, CB8, and the parental mAb
13B8.2 recognized the same complementarity determining region
(CDR)3-like loop region. PDP CB1 was shown to mimic the
biological properties of 13B8.2 mAb in two independent cellular
assays, demonstrating inhibitory activities in the micromolar
range on antigen presentation and human immunodeficiency virus
promoter activation. Our results indicate that the bioactive
CDR-H1 PDP CB1 has retained a significant part of the
parental 13B8.2 mAb properties and might be a lead for the
design of anti-CD4 peptidomimetics of clinical interest. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The CD4 molecule is a transmembrane glycoprotein of 58
kDa mainly expressed on the surface of mature T cells [1,2].
CD4 is composed of four extracellular domains (D1^D4),
which share homology with the immunoglobulin VU region
[3,4], a transmembrane portion and a cytoplasmic tail non-
covalently associated with the protein tyrosine kinase p56lck
[5]. The CD4 molecule acts as co-receptor for the major his-
tocompatibility complex (MHC) class II and is a molecular
partner for the T cell receptor (TcR) [6^9]. This trimolecular
complex is critical for optimal activation of T cells [10^12].
Besides this physiological function, CD4 serves as a receptor
for envelope glycoprotein of the human immunode¢ciency
virus (HIV), contributing to virus entry into cells [13].
Interactions with both MHC class II and gp120 involve
residues of the complementarity determining region (CDR)2-
like loop in D1 of CD4 [14^18]. On the opposite side of the
D1 domain of CD4, the CDR3-like loop displays biological
activities by acting as a target for molecules that inhibit im-
mune response and HIV replication [19^22]. This latter role in
a cascade of postbinding events has been demonstrated both
by CDR3-like peptide analogs [23^27] and by anti-CDR3-like
monoclonal antibodies (mAbs) such as 13B8.2 mAb [28^30].
The biological properties of 13B8.2 mAb have lead to its
inclusion in phase I/II trials of HIV-infected patients [31^33].
Clinical applications of full-length murine mAbs may be
limited by their high immunogenicity, their inability to cross
the blood/brain barrier, and their limited ability to penetrate
cells and tissues [34]. To overcome such problems, we have
developed the concept of paratope-derived peptides (PDPs)
which correspond to short amino acid sequences derived
from antibody variable regions and which display antigen
binding and biological activities [35^38]. These small mole-
cules are screened from a systematic exploration of antibody
variable domain sequences by the Spot method [39,40]. Given
the pharmaceutical interest of 13B8.2 mAb, it appeared to us
attractive to design such anti-CD4 PDPs.
To this end, we have identi¢ed nine PDPs from the 13B8.2
variable regions by using the Spot method. All the selected
PDPs, prepared in a soluble cyclic form, were able to bind
histidine-tagged recombinant CD4 (His6-sCD4) expressed in
baculovirus. MAb 13B8.2 speci¢cally displaced the binding of
His6-sCD4 to PDPs CB1 and CB8, indicating that anti-CD4
PDPs recognize an epitope on the CD4 molecule closely re-
lated or similar to that identi¢ed for the 13B8.2 parental
mAb. PDP CB1 displayed biological properties very similar
to those of the parental 13B8.2 mAb, inhibiting in vitro anti-
gen presentation and HIV-1 promoter activation. Taken to-
gether, our results indicate that the bioactive PDP CB1, de-
rived from the CDR-H1 region of the anti-CD4 13B8.2 mAb,
could be a valuable tool for the design of anti-CD4 peptido-
mimetics.
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 3 0 3 6 - 8
*Corresponding author. Present address: CNRS-UMR 5094, Institut
de Biotechnologie et Pharmacologie, 15 avenue Charles Flahault,
34060 Montpellier Cedex 2, France. Fax: (33)-4-6754 8610.
E-mail address: chardes@pharma.univ-montp1.fr (T. Charde's).
1 VH and VL sequences from 13B8.2 mAb have been submitted to the
EMBL database under the accession numbers AJ279001 and
AJ27900, respectively.
Abbreviations: mAb, monoclonal antibody; CDR, complementarity
determining region; PDP, paratope-derived peptide; VH, variable re-
gion of the heavy chain; VU , variable region of the U light chain
FEBS 25428 5-11-01
FEBS 25428 FEBS Letters 508 (2001) 67^74
2. Materials and methods
2.1. Reagents, cell lines and vectors
Recombinant human soluble CD4 (rhCD4) was obtained from Re-
pligen (Needham, MA, USA). rhCD4 was biotinylated using a com-
mercial reagent (Amersham Pharmacia Biotech, Cleveland, OH, USA)
according to the manufacturer’s instructions and stored in PBS at
320‡C until use. 13B8.2 mAb [19,31] was obtained from Immuno-
tech-Coulter (Marseille, France). The murine hybridoma cell line that
produces 13B8.2 mAb (IgG1/U [19]) was kindly provided by Dr. D.
Olive and Dr. C. Mawas (INSERM U119, Marseille, France). The
pMV7-T4 plasmid, encoding the full-length CD4-cDNA sequence
[41,42], was a kind gift from Dr. Q.J. Sattentau (Centre d’Immuno-
logie de Marseille-Luminy, Marseille, France). The human lympho-
blastoid B cell line EBV-Lu, expressing the HLA DR5,6, DRB52,
DQ6,7, and A2 molecules, and the murine T cell pdb10F, expressing
human CD4 and pep24 (PAGFAILKCNNKTFNY)-speci¢c chimeric
TcR, have been previously characterized [43,44]. The HeLa P4 HIV-1
LTR L-galactosidase indicator cell line [45] was provided by Dr. O.
Schwartz (Institut Pasteur, Paris, France).
2.2. Cloning and sequencing of 13B8.2 mAb VH and VL genes
All the general procedures concerning the cloning and sequencing
of 13B8.2 mAb variable regions have been described [46].
2.3. Peptide synthesis on cellulose membranes
202 overlapping dodecapeptides frameshifted by one residue repre-
senting the VH and VL sequences of 13B8.2 mAb on a cellulose mem-
brane were synthesized according to previously described protocols
[37].
2.4. Assay for sCD4 interaction with cellulose-bound peptides
The saturated membrane was incubated with a 20 nM solution of
biotinylated-rhCD4 for 2 h at 37‡C. Bound biotinylated-rhCD4 was
detected by incubating the membrane for 1 h at 37‡C with a 1:3000
solution of alkaline phosphatase-conjugated streptavidin (Sigma, St.
Louis, MO, USA) and subsequent addition of 5-bromo-4-chloro-3-
indolyl phosphate substrate. Inhibition of biotinylated-rhCD4 binding
was performed as described above, except that biotinylated-rhCD4
(20 nM) was pre-incubated for 18 h at 4‡C with 13B8.2 mAb (6.25
WM). In all cases, the reactivity of the spots was evaluated by scanning
the membrane and measuring the intensities of the spots with the NIH
image 1.61 software [39].
2.5. Synthesis of soluble peptides
The nine selected PDPs, named CB1 to CB9 (see Fig. 2, right panel
for sequences), a scrambled form of PDP CM9 (ScCM9:
GSDQWNKMQYYP) [35], a scrambled form of the CD4-derived
CDR3-like peptide (ScCDR3-like : KEEICEVEDQTY), and an unre-
lated peptide (Dig97c: FGDYYCLQYASS, derived from the CDR-
L3 region of the anti-digoxin 1C10 mAb), with Lys^Cys residues
added to both carboxyl- and amino-termini of all peptides, were syn-
thesized by Fmoc solid-phase synthesis on an AMS422 robot
(Abimed, Langelfeld, Germany), cyclized and puri¢ed as described
previously [35]. Lys and Cys residues were added, respectively, to
improve the solubility and to permit the cyclization of the peptides.
All peptides showed homogeneity in high performance liquid chroma-
tography at the expected monomeric molecular weight. Thereafter, all
peptides were resuspended in deionized water, except for the scCDR3-
like peptide which was suspended in a 10% acetonitrile solution and
the CB8 PDP in a 20% acetonitrile solution.
2.6. Baculovirus expression of recombinant His6-sCD4
The nucleotide sequence of soluble CD4 (D1^D4) was sorted by
polymerase chain reaction from the pMV7-T4 plasmid by using the
sense primer SCD4FB (5P-GAAGATCTATGAACCGGGGAGTCC),
which matches codons 1 to 6, and the anti-sense primer SCD4RTB
(5P - GAAGATCTTCAATGGTGATGGTGGTGGTGACCTAATG-
CGGCCATTGGCTGCACCGGG), which contains the reverse com-
plement of codons 367 to 372 of CD4 and encodes the His6-tag and a
BglII restriction site. Following sub-cloning into the pGEM-T vector
(Promega, Madison, WI, USA), the sCD4 sequence was veri¢ed by
using the dideoxy termination method with the T7 sequencing kit
(Pharmacia, Uppsala, Sweden). The BglII-linearized His6-sCD4 frag-
ment was cloned into the p119L baculovirus transfer vector to allow
the expression of His6-sCD4 under the P10 promoter. After trans-
fection of Spodoptera frugiperda Sf9 cells (ATCC CRL 1711), re-
combinant baculoviruses were further puri¢ed by using a plaque assay
and propagated in Sf9 cells [47,48]. Supernatant of Sf9 cells infected
with the His6-sCD4 recombinant baculovirus in a spinner culture (106
cells/ml) were harvested 6 days post-infection and clari¢ed by centri-
fugation at 1000Ug for 5 min.
2.7. Puri¢cation and characterization of His6-sCD4
Puri¢cation of the His6-sCD4 product was carried out by using Ni-
NTA agarose beads (Qiagen, Chatsworth, CA, USA) according to the
manufacturer’s procedure with minor modi¢cations. Brie£y, the clari-
¢ed baculovirus supernatant was dialyzed against washing bu¡er (50
mM NaH2PO4, 500 mM NaCl, 5 mM imidazole) for 24 h at 4‡C. Ni-
NTA agarose beads were then added to a ¢nal concentration of 5%,
and the binding of His6-sCD4 was performed for 18 h at 4‡C. Beads
were washed with 8 volumes of washing bu¡er and His6-sCD4 was
eluted as 1 ml fractions with 3 volumes of elution bu¡er (50 mM
NaH2PO4, 500 mM NaCl, 300 mM imidazole). The Ni-NTA agarose
beads were regenerated with 1 M imidazole. All puri¢cation fractions
were checked for the presence of His6-sCD4 by enzyme-linked immu-
nosorbent assay (ELISA) and Western blot using the anti-CD4 13B8.2
mAb as detection reagent.
2.8. Binding studies of PDPs to CD4
Three replicates corresponding to 10-fold serial dilutions of the nine
cyclic PDPs (CB1^CB9) were coated overnight at 4‡C onto 96-well
ELISA plates (Nunc, Paisley, UK) with an initial peptide concentra-
tion of 50 WM. Four washes in 160 mM PBS, pH 7.2, containing 0.1%
Tween 20 (PBS-T) were performed before and after saturating the
wells with 1% non-fat dry milk in PBS-T for 1 h at 37‡C. Thereafter,
100 Wl of 20 nM His6-sCD4 was added to each well. Following a 2 h
incubation and four washes in PBS-T, bound His6-sCD4 was detected
by addition of 100 Wl of a 1:2000 solution of peroxidase-conjugated
anti-His6 mAb (Sigma) and subsequent addition of peroxidase sub-
strate. Absorbance was measured at 490 nm.
2.9. Binding speci¢city of PDPs CB1 and CB8 to CD4
Inhibition of His6-sCD4 binding to PDPs was performed by an
ELISA method with PDPs CB1 and CB8 coated at 12.5 and 2.5
WM, respectively, as capture reagent. A 20 nM solution of His6-
sCD4 showing an absorbance at 490 nm of 1.0 was co-incubated
with two-fold serial dilutions of 13B8.2 mAb. Three replicates were
tested for each dilution with an initial mAb concentration of 3 WM.
His6-sCD4 binding was evaluated as described above.
2.10. Interleukin-2 (IL-2) secretion assay following antigen
presentation
EBV-Lu antigen-presenting cells (106 cells/ml), overnight pulsed
with the pep24 stimulator peptide (75 WM) from HIV gp120 [44],
were co-cultured with pdb10f responder cells (4U105 cells/ml) in the
presence or absence of inhibitor PDPs or mAbs for 24 h. Thereafter,
100 Wl of supernatant was harvested and tested for IL-2 secretion
using an ELISA commercial kit (Pharmingen, San Diego, CA,
USA). A positive control for IL-2 secretion was performed as de-
scribed above except that activation of pdb10F cells was done using
a murine anti-CD3 antibody at a concentration of 0.6 nM (Pharmin-
gen) [49].
2.11. HIV-1 promoter activation assay
HeLa P4 indicator cells (8U104 cells/ml) were cultured in medium
supplemented or not with 1000 TCID50 of infectious HIV-1Lai in the
presence or absence of peptides or mAb for 3 days, harvested and
lysed. The L-galactosidase activities were then determined as previ-
ously described [45], by measuring the absorbance at 410 nm.
3. Results
3.1. Characterization of nine peptides from 13B8.2 mAb
demonstrating CD4 binding ability
The nucleotide sequences of the VH and VL domains of
13B8.2 mAb were established according to the general proce-
dure described by Charde's et al. [46] and made available from
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the EMBL database under the accession numbers AJ279001
and AJ27900, respectively. The complete amino acid sequen-
ces of both chains are given in Fig. 1 with somatic mutations
indicated. Genetic analysis of these sequences showed that the
VH region of 13B8.2 mAb resulted from the rearrangement of
VH2-DQ52-JH3 genes and that the VL region resulted from a
VU12/13-JU2 gene rearrangement. More precisely, computer-
assisted comparison of these sequences showed that the VH
and VL genes of 13B8.2 displayed signi¢cant homologies with
Ox2 [50] and k2 [51] germline genes, respectively (Fig. 1). It is
worth noting that no signi¢cant homology was found between
13B8.2 mAb variable sequences and other anti-CD4 variable
domains.
202 overlapping dodecapeptides frameshifted by one resi-
due, corresponding to the deduced amino acid sequence of
VH and VL from 13B8.2 mAb, were synthesized on a cellulose
membrane by using the Spot method. The anti-CD4 immuno-
reactivity of these peptides was assessed by incubating the
membrane with biotinylated-rhCD4. The results are quantita-
tively expressed in Fig. 2 (left panel) in which the reactivity of
peptides that comprise at least one residue from the CDRs are
boxed. Anti-CD4 reactivity was observed for peptides includ-
ing amino acids from ¢ve of the six CDRs of 13B8.2 mAb
(peptides 20, 22, 28^35; 46, 48^52, and 93^97 for CDR-H1,
CDR-H2, and CDR-H3, respectively, and 22, 23, 29^34; 83^
89, and 91 for CDR-L1 and CDR-L3, respectively). Anti-CD4
activity was also obtained for peptides containing residues
from the framework, mainly £anking the CDRs (peptides
18, 36^38 and 66^71 for VH, and 35^38 and 57^61 for VL)
but the majority of peptides comprising only framework res-
idues did not display any signi¢cant binding activity. This
reactivity was drastically decreased when biotinylated-rhCD4
was pre-incubated with an excess of 13B8.2 parental mAb
(data not shown). Nine peptides (29, 30, 48, 52, 90 and 94
for VH and 22, 29 and 86 for VL), named CB1 to CB9 (Fig. 2,
right panel), were selected for further study in a soluble form.
These peptides, except for 22 and 29 from CDR-L1, showed
the highest anti-CD4 activity and comprised at least 50% of
residues belonging to CDRs. Since the most reactive peptides
derived from the CDR-L1 showed less than 50% of residues
from the CDR (peptides 31 and 34), we selected two adjacent
reactive peptides, namely, 22 and 29. Except for PDP CB4,
that exclusively comprised amino acids from the CDR-H2, all
selected PDPs comprised amino acids from both CDR and
framework sequences.
3.2. Soluble cyclized selected PDPs demonstrate CD4 binding
activity
Peptides selected according to the Spot results were synthe-
sized and N- to C-terminus cyclized through cysteine oxida-
tion. Cyclization has already been demonstrated as a useful
tool to improve antigen binding [36]. The ability of recombi-
nant His6-sCD4 expressed in baculovirus to speci¢cally bind
cyclic PDPs was assessed by ELISA (Fig. 3). All the selected
PDPs, except CB3 from the CDR-H2, showed a dose-depen-
dent CD4 binding activity. Three of them, PDPs CB1 and
CB2 derived from the 13B8.2 CDR-H1 region, and PDP
CB8 derived from the 13B8.2 CDR-L1 region, displayed
high binding activity in a 0.5^50 WM concentration range.
The non-reactivity of irrelevant ScCDR3-like and ScCM9
peptides indicated that the addition of lysine and cysteine
residues for solubilization and cyclization of peptides had no
e¡ect on CD4 binding. Since PDPs CB1 and CB2 only di¡er
by one amino acid residue, we focused our attention on PDP
CB1, derived from the CDR-H1, and PDP CB8, derived from
the CDR-L1 of 13B8.2 mAb for further speci¢city studies.
3.3. PDPs CB1 and CB8 speci¢cally bind to CD4 on the same
region as that of parental 13B8.2 mAb
The ability of the parental mAb 13B8.2 to displace the
binding of PDPs CB1 and CB8 to His6-sCD4 was studied
by using an ELISA inhibition assay. The absorbance of resid-
ual His6-sCD4 binding to PDPs was measured at 490 nm and
expressed as percent inhibition of the binding (Fig. 4). We
found that 13B8.2 mAb was able to displace the binding of
His6-sCD4 (20 nM), in a dose-dependent manner, to both
coated PDPs CB1 (12.5 WM) and CB8 (2.5 WM) with similar
e⁄ciencies. A 50% inhibition of binding of PDPs CB1 and
CB8 to CD4 was obtained for 13B8.2 mAb concentrations of
20 and 8 nM, respectively. No inhibition was found when
using the IgG1 isotype-unrelated anti-digoxin mAb 1C10,
demonstrating the speci¢city of the competition studies.
Similar results were obtained in a symmetric experiment in
which the binding of His6-sCD4 (20 nM) to 13B8.2 mAb (0.3
nM) was inhibited by various concentrations of PDPs CB1
Fig. 1. Amino acid sequences of VH and VL domains of the anti-
CD4 mAb 13B8.2. The sequences were deduced from nucleotide se-
quences of both regions (submitted to the EMBL database under
the accession numbers AJ279001 and AJ279000, respectively). So-
matic mutations between 13B8.2 VH versus Ox2 germline VH and
13B8.2 VL versus k2 germline VL, respectively, are indicated. Num-
bering of the amino acids is that of Kabat et al. [73]. Boldfaced res-
idues belong to the CDRs.
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and CB8 (data not shown). A 50% inhibition of binding of
His6-sCD4 to 13B8.2 mAb were obtained for concentrations
of PDPs CB1 and CB8 up to 75 and 125 WM, respectively.
Taken together, these data are consistent with the hypothesis
that 13B8.2 mAb, CB1, and CB8 peptides recognized the
same antigenic region on the CD4 molecule.
3.4. PDP CB1 is able to inhibit IL-2 secretion following
antigen presentation
The stimulation of pdb10f responder T cells by pep24-
pulsed EBV-Lu APC leads to the lymphocyte secretion of
IL2 [43,44]. This T cell activation model is speci¢c since no
IL-2 secretion occurs when EBV-Lu antigen-presenting cells
are pulsed with a non-stimulator pep23 antigen. We checked
the viability of the pdb10f responder cell line by activating
cells with a murine anti-CD3 mAb which induced IL-2 secre-
tion (data not shown). As shown in Table 1, the irrelevant
anti-digoxin mAb 1C10 showed no inhibitory activity of IL2
secretion in contrast to the anti-CD4 13B8.2 mAb which
blocked the IL2 production (99.6 þ 0.2% inhibition). As com-
pared to the irrelevant ScCM9 peptide showing no inhibition,
PDP CB1 displayed inhibitory activity of IL2 secretion in a
125^250 WM concentration range. The biological activity of
PDP CB2 was found to be very moderate since no activity
was found at a concentration lower than 250 WM.
The lack of activity for PDP CB8 was found to be consec-
utive to cell death, probably due to the presence of 20% ace-
tonitrile in the bu¡er used to solubilize the peptide. The other
selected PDPs demonstrated no or extremely low blocking of
IL2 secretion. Taken together, these results indicate that, as
already demonstrated for other anti-CD4 mAbs [52,53], the
CDR-H1-derived PDP CB1 is able to inhibit the antigen-pre-
senting function, a biological property also demonstrated for
the 13B8.2 parental mAb.
Fig. 2. Quantitative analysis of the binding of biotinylated-rhCD4 to overlapping dodecapeptides derived from the variable sequences of anti-
CD4 13B8.2 mAb. On the left, the reactivity of peptides derived from the VH sequence (numbered 1 to 106) and the VL sequence (numbered 1
to 96) was evaluated after incubation of the membrane with 20 nM biotinylated-rhCD4 (cuto¡ taken at 50 arbitrary units, dotted line). Pep-
tides comprising at least one residue from the CDRs sequences are boxed (H1, H2 and H3 and L1, L2 and L3 correspond to CDR1, CDR2,
and CDR3 of the heavy and light chains, respectively). On the right, sequences of the nine PDPs selected for further functional characteriza-
tion, indicated by asterisks, are shown. Numbering of the amino acids is that of Kabat et al. [73]. Boldfaced residues belong to the CDRs.
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3.5. PDP CB1 displays a strong capacity to inhibit HIV-1Lai
LTR-driven L-galactosidase reporter gene expression
The parental mAb 13B8.2 has been previously demon-
strated to be an inhibitor of viral particle production by cells
infected with HIV-1Lai, HIV-1Eli, HIV-1Sf2, HIV-1Ger and
HIV-2Rod strains [13,54]. In addition, viremia negativation
has been observed for HIV-infected patients treated with
13B8.2 antibody, demonstrating its e⁄ciency towards primary
clinical isolates [31,32]. In order to assess the ability of se-
lected 13B8.2 PDPs to inhibit HIV-1 promoter activity, we
measured the L-galactosidase reporter gene expression after
infection of the indicator cell line HeLa P4 cultured for
3 days in the presence of peptides. As shown in Fig. 5A, the
1C10 mAb did not display any inhibitory activity in contrast
to the parental 13B8.2 mAb which inhibited HIV promoter
activation. Culturing infected HeLa P4 cells with irrelevant
Dig97c or ScCM9 peptides did not a¡ect L-galactosidase ex-
pression, whereas a signi¢cant inhibition was found when the
cells were cultured with a 50 WM solution of 13B8.2 PDPs
CB1, CB2 and CB5.
The lack of activity for PDP CB8 was found, in this assay,
also to be consecutive to cell death caused by the presence of
20% acetonitrile in the bu¡er used to solubilize the peptide
since no inhibition was observed with the PDP CB1 diluted in
the same 20% acetonitrile bu¡er (data not shown). In Fig. 5B,
we demonstrate that the inhibitory e¡ect of CB1 is dose-de-
pendent, with an IC50 for CB1 of about 15 WM, whereas the
IC50 of the parental mAb was found to be 5 nM. These results
indicate that the CDR-H1-derived dodecapeptide CB1 has
anti-viral activity, as already demonstrated for the parental
anti-CD4 13B8.2 mAb.
4. Discussion
The CD4 molecule plays a key role both in the MHC class
II-restricted immune response and the human immunode¢-
ciency virus infection process by acting as a receptor either
for the TcR^antigen engagement complex or for the envelope
glycoprotein gp120 of HIV [7,9,55,56]. In these two cases,
CD4 has been demonstrated to induce signal transduction
leading to T cell activation [12,19,21,22]. Both of these mech-
anisms can be inhibited by treatment with anti-CD4 mAbs
including murine 13B8.2 mAb [28^30]. Such inhibitory prop-
erties have led to the inclusion of 13B8.2 mAb in phase I/II
trials in HIV-infected patients [31^33]. To avoid problems
encountered when using mAbs in therapeutic approaches,
such as immunogenicity and low tissue di¡usion, we designed
and synthesized PDPs from the 13B8.2 anti-CD4 mAb.
Fig. 4. Epitope speci¢city of the binding of PDPs CB1 and CB8 to
sCD4. An ELISA was performed by coating CB1 (12.5 WM) (b)
and CB8 (2.5 WM) (a) onto plates. Binding of His6-sCD4 (20 nM)
to PDPs was then inhibited by various dilutions of 13B8.2 mAb.
Percent inhibition of the binding was calculated with reference to
the His6-sCD4 binding to PDPs in the absence of 13B8.2 mAb. In-
hibition values were calculated from the mean 490 nm absorbances
of triplicate determinations. Mean absorbance at 490 nm ranged
from 0.20 (background level) to 1.25 (in absence of inhibitor).
Table 1
Inhibition of IL-2 secretion by pdb10f cells, sensitized with pep24-
stimulated EBV-Lu presenting cells, and cocultured with cyclic
PDPs
Inhibitor Concentration
(WM)
% Inhibition of
IL-2 secretiona
13B8.02mAb 0.5 99.6 þ 0.2b
1C10mAbc 0.5 00.0
CB1 250 58.3 þ 1.9b
125 20.0
62.5 00.0
CB2 250 67.5 þ 12.0b
125 00.0
62.5 00.0
CB3 250 07.0
CB4 250 04.0
CB5 250 00.0
CB6 250 09.0
CB7 250 00.0
CB8 250 NMd
CB9 250 00.0
ScCM9c 250 00.0
aCalculated with respect to IL-2 secretion value in absence of inhibi-
tor, taken as reference. Mean 490 nm absorbance values ranged
from 0.05 for unactivated pdb10f cells to 1.40 for activated pdb10f
cells in absence of inhibitors.
bMean þ S.E.M. of three independent experiments.
cNegative controls.
dNot measurable.
Fig. 3. ELISA binding assay of His6-sCD4 (20 nM) onto adsorbed
cyclic peptides derived from the sequence of 13B8.2. Each value rep-
resents the mean þ S.E.M. of triplicate determinations. Irrelevant
peptides (ScCDR3-like and ScCM9) were used as negative controls.
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In this study, we demonstrated that the CDR-H1-derived
PDP CB1 displays signi¢cant and speci¢c biological proper-
ties mimicking those of the parental anti-CD4 13B8.2 mAb.
Firstly, in an in vitro model of MHC class II-restricted im-
mune response, we demonstrated that anti-CD4 PDP CB1, as
well as parental mAb 13B8.2, inhibits IL2 secretion by acti-
vated T cells following antigen presentation; this inhibitory
e¡ect, classically observed for anti-CD4 mAbs [52,53], was
dose-dependent. Since, anti-CD4 mAbs have been described
to prevent T cells from IL2-induced proliferation and B cell
adhesion through inhibition of Ca2 and p21ras signaling
pathways [57,58], it remains to be assessed whether our anti-
CD4 PDPs could interfere with such mechanisms. The e¡ect
of CB1 in an in vivo model of immune disorder remains to be
investigated, as it was done for anti-CD4 CDR3-like-derived
analogs in a murine experimental allergic encephalomyelitis
model [59]. Secondly, we found that the PDP CB1 inhibited
HIV-1 promoter activation, as 13B8.2 mAb does [29]. The
mechanism by which 13B8.2 mAb exerts this anti-HIV prop-
erty has been related to inhibition of signal transduction, in-
volving the extracellular regulated kinase/mitogen-activated
protein kinase kinase signaling pathway [13]. We are currently
investigating whether CB1 also acts by disrupting the same
signal transduction machinery, thereby preventing HIV pro-
virus transcription.
We found that peptides CB1 and CB8 displayed speci¢c
anti-CD4 binding activity. We recall, however, that a rela-
tively high concentration of peptides was needed in our ex-
periments to demonstrate e⁄cient biological activity with re-
gard to the e⁄cient antibody dose. To explain this di¡erence,
we measured the binding of CD4 to PDP CB1 and observe a
50% decrease in binding when following pre-incubation of the
peptide for 25 min at 37‡C in a bu¡er containing 10% fetal
calf serum (data not shown). This ¢nding strongly suggests
that the requirement for high concentrations of CB1 to ob-
serve a biological e¡ect re£ects degradation of the peptide in
the culture medium. The use of D-amino acids for peptide
synthesis could be of interest as a means of improving their
metabolic stability [60].
Concerning PDP CB8, the biological properties of this pep-
tide remain to be investigated in bu¡er solutions compatible
with the cellular assays. A longer sequence of PDP CB8 in-
cluding hydrophilic £anking residues is under analysis to im-
prove the solubility of the peptide and to avoid the use of
organic solvent. It would be of great interest to investigate
this point because of a high sequence/position homology be-
tween this CDR-L1-derived PDP CB8 and a previously char-
acterized CDR-L1-derived PDP, the CM9 peptide, derived
from the anti-CD4 ST40 mAb that inhibits HIV transcription
[35]. Comparison of alanine-scanning analysis of these two
peptides indicated that similar residues located at the same
positions, i.e. Tyr32, Trp35, Tyr36, Lys39, contribute to CD4
binding ([36] and unpublished data). This may help us under-
stand the structure^function relationship in these series of
anti-CD4 mAb-derived bioactive molecules.
The systematic exploration of the 13B8.2 mAb paratope has
led us to the characterization of PDPs CB1 and CB8, display-
ing high anti-CD4 reactivity and including residues from the
CDRs and from the framework £anking these CDRs. The
role of residues outside the CDRs (i.e. Trp36 and Arg38 in
the CB1 sequence, and Tyr36 in the CB8 sequence) has already
been described as being important in structuring the active
CDR loops in the full mAb paratopes [61,62]. Moreover,
Park et al. [63] demonstrated the relevant importance of add-
ing aromatic residues to improve the e⁄ciency of their CDR-
H3-derived anti-HER2/neu peptide mimetics. The addition of
aromatic residues has been found to be a valuable strategy for
enhancing stability, folding, and avidity of peptidomimetics
[25,64^66]. This could explain the high reactivity obtained
for PDP CB1, in which the natural Trp36 residue may have
such function. We demonstrated di¡erences, both in anti-CD4
binding activity and in biological properties, between PDPs
CB1 and CB2, that are frameshifted by only one residue. Two
key points may explain these di¡erences. Firstly, PDP CB2
contains the Pro41 residue which may constrain the peptide in
an unfavorable conformation. Secondly, in PDP CB2 the
Leu29 residue is absent; the Leu29 residue has been demon-
strated to be part of the Vernier zone [67], already described
to stabilize Ag/Ab interactions. These two factors may con-
tribute to twisting PDP CB2 into a less favorable conforma-
tion for CD4 binding, thereby explaining the decreased bio-
Fig. 5. Inhibition of LTR-driven L-galactosidase gene expression in-
duced by HIV-1Lai following incubation with cyclic PDPs. A: Per-
cent inhibition of L-galactosidase expression in HIV-1Lai-infected
HeLa P4 cells cultured in the presence of 13B8.2 mAb and 1C10
mAb, an irrelevant anti-digoxin mAb, at 0.5 WM, and cyclic PDPs
at 50 WM. ScCM9 or Dig97c peptides were used as negative con-
trols. B: Dose^response curves for HIV-1Lai-infected HeLa P4 cells
cultured in the presence of various concentrations of 13B8.2 mAb
(a) and PDP CB1 (b). In all cases, each value is the mean þ S.E.M.
of at least three independent experiments. Mean absorbance at 410
nm ranged from 0.014 for uninfected HeLa P4 cells to 0.658 for
HIV-1Lai-infected cells.
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logical properties of CB2. Taken together, these data con¢rm
the capacity of the Spot method in de¢ning antigen-speci¢c
peptides derived from a mAb paratope that present paratope-
derived residues in an environment compatible for antigen
binding.
The CDR3-like loop of domain 1 of CD4, and more pre-
cisely the negatively charged residues Glu91 and Glu92, has
been shown to play a role in activating T cell signal trans-
duction [20,21] ; Glu91 and Glu92 are also involved in the
13B8.2 paratope [16]. Inhibition studies demonstrated that
PDP CB1 and 13B8.2 mAb speci¢cally compete for CD4
binding on the same region of the molecule. Alanine scanning
of the CB1 sequence showed that the main contributor resi-
dues are positively charged (i.e. His35 and Arg38, unpublished
data), thereby possibly interacting with its negatively charged
epitope on the CD4 molecule. The CDR3-like loop from the
D1 domain of CD4 has been reported to be involved in one of
the two potential CD4 dimerization sites [20,21,68,69]. The
dimerization/oligomerization processes have been shown to
be necessary for optimal activation of CD4 T lymphocytes
[16,26,70^72]. It is therefore possible that the inhibitory e¡ects
of PDP CB1 on T cell stimulation and HIV-1 promoter acti-
vation could result from a CD4 dimerization/oligomerization
disruption, thereby uncoupling the CD4 molecule from the
signal transduction machinery. Even if this molecular mecha-
nism remains to be established, our approach has led to the
characterization of the anti-CD4 PDP CB1. This kind of small
bioactive molecule could be a lead for the development of a
second generation of more potent and stable molecules of
pharmaceutical interest.
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